

# QUANTITY LIMIT CRITERIA

**BRAND NAME**  
(generic)**GRALISE**  
(gabapentin extended-release tablet)**HORIZANT**  
(gabapentin enacarbil extended-release tablet)**Status: CVS Caremark® Criteria****Type: Quantity Limit****POLICY****FDA-APPROVED INDICATIONS****Gralise**

Gralise is indicated for the management of postherpetic neuralgia.

Gralise is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

**Horizant****Treatment of Restless Legs Syndrome**

Horizant is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.

Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

**Management of Postherpetic Neuralgia**

Horizant is indicated for the management of postherpetic neuralgia (PHN) in adults.

**INITIAL LIMIT QUANTITY**

**Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength**

<b>Drug</b>	<b>1 Month Limit*</b>	<b>3 Month Limit*</b>
Gralise 300 mg (gabapentin extended-release)	150 tablets / 25 days	450 tablets / 75 days
Gralise 450 mg (gabapentin extended-release)	90 tablets / 25 days	270 tablets / 75 days
Gralise 600 mg (gabapentin extended-release)	90 tablets / 25 days	270 tablets / 75 days
Gralise 750 mg (gabapentin extended-release)	60 tablets / 25 days	180 tablets / 75 days
Gralise 900 mg (gabapentin extended-release)	60 tablets / 25 days	180 tablets / 75 days
Horizant 300 mg (gabapentin enacarbil extended-release)	60 tablets / 25 days	180 tablets / 75 days

Gralise, Horizant Limit Policy 3911-H 06-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428B 021423

Horizant 600 mg  
(gabapentin enacarbil extended-release)

60 tablets / 25 days

180 tablets / 75 days

*\*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

## **REFERENCES**

1. Gralise [package insert]. Morristown, NJ: Almatica Pharma LLC.; March 2023.
2. Horizant [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed April 20, 2023. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/20/2023).